We are live on ! Find out more
KZIA

Kazia Therapeutics

10 hedge funds and large institutions have $4.01M invested in Kazia Therapeutics in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

0% less ownership

Funds ownership: 0.01%0.01% (-0%)

20% less capital invested

Capital invested by funds: $5.03M → $4.01M (-$1.02M)

33% less funds holding

Funds holding: 1510 (-5)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

95% less call options, than puts

Call options by funds: $4K | Put options by funds: $84K

Holders
10
Holders Change
-5
Holders Change %
-33.33%
% of All Funds
0.15%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
5
Reduced
2
Closed
6
Calls
$4K
Puts
$84K
Net Calls
-$80K
Net Calls Change
-$373K

KZIA Hedge Fund Activity: Q4 2021 in Review

10 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q4 2021, worth a combined $4.01M — down 20% from $5.03M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of KZIA and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 5 added.

The largest buyer was Envestnet Asset Management, opening a new position worth an estimated $263K. The largest seller was Citadel Advisors, exiting entirely with an estimated $176K sold.

  • 10 institutional investors held Kazia Therapeutics (KZIA) as of Q4 2021, down from 15 in Q3 2021.
  • Funds reported $4.01M of Kazia Therapeutics stock for Q4 2021, down 20% quarter-over-quarter.
  • 1 fund opened new Kazia Therapeutics positions in Q4 2021 and 6 closed out, a net change of -5 holders.
  • The largest Kazia Therapeutics buyer in Q4 2021 was Envestnet Asset Management, an estimated $263K added.
  • The largest Kazia Therapeutics seller in Q4 2021 was Citadel Advisors, an estimated $176K sold.

Based on aggregated 13F filings for Q4 2021.